

PROGRAMME

EUROPEAN CENTRALISED PROCEDURE AND PAEDIATRIC REGULATION

Pavia, 2-4 September, 2008
Fondazione Salvatore Maugeri Via Maugeri, 4 – Pavia (Italy)

1st Topic: European Centralised procedure from A to Z

2 September 2008

Chairmen: Eugenio Muller - Enrico Bosone

9.30 Introductory Remarks

Angiolino Stella, Chancellor of the University of Pavia Marcello Imbriani, Scientific Director S. Maugeri Foundation Guido Rasi, Director of AIFA Sergio Dompé, President of Farmindustria

10.00 Introduction

The Gianni Benzi Foundation role and perspective Vittorio Silano

Chairmen: Mario Cazzola - Cesare Fieschi

10.30 **Opening Remarks**

The EMEA and the future of pharmaceuticals for human use *Thomas Lönngren*

11.00 A European Network for Education in the Regulatory Affairs context *Pino Nisticò*

11.30 Coffee Break

Chairmen: Vittorio Silano - Walter Bianchi

- 11.45 Tools for development of innovative drugs: Scientific Advice (SA) and Protocol Assistance (PA)
 - When a SA or a PA are convenient
 - How they work
 - Many advantages and few warnings

Hans-Georg Eichler /Jacques Mascaro /Jean-Pierre Osselaere

- 12.45 Presubmission activities
 - When they are appropriate
 - What you need to know

Jean-Pierre Osselaere/Henk Schuring/ Hans-Georg Eichler

14.00 Lunch

ITALY



Chairmen: Walter Bianchi - Marcello Tonini

15.00 The application and the first period of the Assessment

- Strategies in preparing the e-CTD
- How to work with EMEA Henk Schuring/Pino Nisticò
- 16.00 Coffee break

16.15 Objections and answers

- Minor and major objections
- Main reasons for major objections
- How to answer to the objections

Jacques Mascaro/Henk Schuring/Pino Nisticò

17.15 **Q&A**

All speakers

3 September 2008

Chairmen: Enrico Bosone - Jean-Pierre Osselaere

9.00 Oral explanation and dialogue with Rapporteur, Co-Rapporteur and Project Manager

- How to understand the objections
- Examples of positive dialogue
- 25% of withdrawals: when and why
- Orphan drugs and paediatric indications: how the different Committees work together Chris Walker/Eric Abadie

10.00 After the Opinion: commitments and appeals

- Main commitment for oncologic drugs
- Examples of successful appeals

Chris Walker/Eric Abadie

11.00 Coffee Break

Chairmen: Jean-Pierre Osselaere - Enrico Bosone

11.15 From the Opinion to the Decision

- Steps between the Opinion and the Decision
- Labelling for Europe

Chris Walker

11.45 Remarks on Centralised Procedure

- CHMP and Centralised procedure: challenges for the future *Eric Abadie*

12.45 Q&A and final remarks

All speakers

13.15 Lunch



PROGRAMME

EUROPEAN CENTRALISED PROCEDURE AND PAEDIATRIC REGULATION

2nd Topic: The Paediatric Regulation Challenges

3 September 2008

Chairmen: Paola Baiardi - Mariana Catapano

14.30 Introductory remarks on the Paediatric Regulation

- The role of the Paediatric Committee (PDCO): PIP submission, waivers and deferrals Daniel Brasseur
- The Network of Paediatric Networks envisaged in the Paediatric Regulation in supporting paediatric drugs development

Paolo Rossi

- The Task-force in Europe for Drug Development for the Young (TEDDY) role and mission Adriana Ceci

15.30 Early clinical research

- Strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products

Oscar Della Pasqua

- Role of pharmacokinetics in the development of medicinal products in the paediatric population Oscar Della Pasqua
- Introduction to population PK/PD, developmental PK/PD and modelling in paediatric clinical pharmacology Oscar Della Pasqua

16.30 Coffee Break

Chairmen: Jean-Pierre Osselaere - Domenico Criscuolo

16.45 Pharmacogenetics and Pharmacogenomics in paediatric drug developmental phase

- Impact of PGx/PGt in children: relevant aspects

Achille Iolascon/Roberta Russo

- PGx/PGt in children in Europe: where and how

Oscar Della Pasqua

17.15 **Preclinical issues**

- Paediatric specificity for non-clinical tests
- Guideline on the need for non-clinical testing in juvenile animals on human pharmaceuticals for paediatric indications

Annarita Meneguz/Marcello Tonini

17.45 **Q&A**

All speakers

Via Abate Eustasio 30 70010 VALENZANO BA ITALY

Tel.: +39 080 9643146 Fax: +39 080 0999156



4 September 2008

Chairmen: Ian Wong - Paolo Paolucci

9.00 Quality and paediatric formulations

- Development of paediatric formulations Jean Pierre Osselaere/Henk Schuring
- Old Drugs/New formulations

Anu Tummavuori

9.40 Methodology in conducting clinical trials in children

- Formulations of experimental drugs Jean Pierre Osselaere/Henk Schuring
- How to apply for a paediatric clinical trial

Domenico Criscuolo

- Regulatory aspects and PIP application

Mariana Catapano

- Case Studies: focus on specific therapeutic areas- Vaccines Eddie Reilly

11.00 Coffee Break

Chairmen: Maria Mellado Pena - Anu Tummavuori

11.15 Paediatric Research in Europe

- Current status of paediatric research

Paola Baiardi

- Ethical concerns in paediatric clinical trials

Annagrazia Altavilla

- Paediatric Research Costs and Benefits

Massimo lacobelli

12.15 **Q&A**

All speakers

13.00 Lunch

Chairmen: Emilio Perucca - Eddie Reilly

14.00 Pharmacoepidemiology and Pharmacovigilance

- How to collect paediatric data in Europe

Miriam Sturkenboom

- Could pharmacepidemiology guide the drug developmental plan?

Anu Tummavuori

- --Could pharmacoepidemiology guide the SMEs and academic paediatric research?
- Pharmacovigilance and management risks activities addressing the paediatric specificity Katia Verhamme

Chairmen: Adriana Ceci - Enrico Bosone

15.30 Case Studies: Focus on specific therapeutic areas

- Neonatology Marek Migdal
- Oncology Paolo Paolucci
- Respiratory diseases Eugenio Baraldi
- Infectious diseases Maria Mellado Peña
- Epilepsy Emilio Perucca

ITALY



17.00 Q&A, Tests and Conclusion

SPEAKERS' LIST

Eric Abadie, Président du CHMP, EMEA and Conseiller scientifique auprès du Directeur Général, Direction Générale, Afssaps

Annagrazia Altavilla, Assistance Publique des Hôpitaux de Marseille (APHM)-Espace Ethique Méditerranéen

Paola Baiardi, Director, Consortium for Biological and Pharmacological Evaluations (CVBF)

Eugenio Baraldi, Department of Paediatrics Chief of the Unit of Allergy and Respiratory Deseases University of Padova

Walter Bianchi, President, Italian Society of Regulatory Affairs (SIAR)

Enrico Bosone, Director Regulatory Affairs & Compliance, Celgene Srl and SIAR Member of MB

Daniel Brasseur, Chair, Paediatric Committee (PDCO), EMEA

Mariana Catapano, Head of Regulatory Affairs, Consortium for Biological and

Pharmacological Evaluations (CVBF)

Mario Cazzola, Pro-Chancellor University of Pavia, President Consortium for Biological and Pharmacological Evaluations (CVBF)

Adriana Ceci, President, 'Gianni Benzi' Pharmacological Research Foundation and TEDDY NoE Coordinator

Domenico Criscuolo, CHIEF Medical Officer, Creabilis Therapeutics Spa, and IFAPP President

Oscar Della Pasqua, Assistant Professor, Center for Drug Research, Leiden University and Clinical Pharmacology & Discovery Medicine, GlaxoSmithKline

Sergio Dompé, President of Farmindustria

Hans-Georg Eichler, Professor, Vienna University School of Medicine, Senior Medical Officer, EMEA

Cesare Fieschi, Professor of Neurology, University La Sapienza di Roma

Massimo lacobelli, Chief Scientific Officer, Gentium Spa

Marcello Imbriani, Fondazione S. Maugeri, Scientific Director, Pavia

Achille Iolascon, Professor, University Federico II of Naples and CEINGE- Advanced Biotechnologies

Anne Marie Li-Kwai-Cheung, Regulatory Affairs Europe, Genzyme

Operations Centre:

TTAIN



Thomas Lönngren, Executive Director, European Medicines Agency -EMEA

Jacques Mascaro, Vice President Regulatory Affairs and Safety, Elan

Maria José Mellado Pena, Hospital Carlos III and TEDDY NoE-Spain Coordinator

Annarita Meneguz, Director of Biochemical Pharmacology Department, ISS

Marek Migdal, Professor, Neonatologist Children's Memorial Health Institute and member Paediatric Committee (PDCO), EMEA

Eugenio Muller, Professor of Pharmacology, University of Milan

Giuseppe Nisticò, EMEA Board and CHMP member, Director Master in "Scientific and

Regulatory assessment of new drugs" Tor Vergata University – Rome

Jean Pierre Osselaere, Managing Director, EPMC Pharma

Paolo Paolucci, Professor of Paediatrics and Head Department, University of Modena and Reggio Emilia

Emilio Perucca, Professor of Clinical Pharmacology, University of Pavia

Guido Rasi, General Director of Italian Medicines Agency (AIFA)

Eddie Reilly, Head, Regulatory Affairs, Europe & International, Novartis Vaccines and Diagnostics s.r.l

Paolo Rossi, Member Paediatric Committee (PDCO), EMEA and Ospedale Bambino Gesù

Roberta Russo, University Federico II of Naples and CEINGE- Advanced Biotechnologies

Vittorio Silano, President Scientific Committee, 'Gianni Benzi' Pharmacological Research

Angiolino Stella, Chancellor of the University of Pavia

Foundation and President of the EFSA Scientific Commission

Miriam Sturkenboom, Professor of Pharmaco-epidemiology, Erasmus University Medical Center

Marcello Tonini, Professor and Head Department, University of Pavia and Director Master in "Regulatory Sciences - GIANNI BENZI" University of Pavia

Anu Tummavuori, Associate Director European Regulatory Liaison, Celgene International Sarl Switzerland

Katia Verhamme, Senior researcher, Department of Medical Informatics Erasmus University Medical Center

Chris Walker, Senior Manager Regulatory Affairs, Amgen

Ian Wong, Professor of Paediatric Medicines Research, and Director Centre for Paediatric Pharmacy Research

Tel.: +39 080 9643146 Fax: +39 080 0999156